474 results on '"Hirshberg, Boaz"'
Search Results
102. Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes
103. Effects of MEDI0382 on Pancreatic and Incretin Hormones
104. MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study
105. MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus
106. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
107. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
108. Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study
109. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk
110. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
111. Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
112. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
113. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”
114. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
115. Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy
116. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
117. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
118. Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials
119. Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus
120. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
121. Insulinoma
122. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes
123. BASELINE RENAL FUNCTION AND CARDIOVASCULAR RISK IN PATIENTS TREATED WITH SAXAGLIPTIN: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
124. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL
125. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
126. Abstract 53: Health Care Utilization and Cost among Type 2 Diabetes Mellitus (T2DM) Patients with Cardiovascular Disease (CVD) or Cardiovascular Disease Risk Factors
127. Statin and Aspirin Therapy for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
128. Metabolic Function of a Suboptimal Transplanted Islet Mass in Nonhuman Primates on Rapamycin Monotherapy
129. Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
130. Challenges in developing endpoints for type 1 diabetes intervention studies
131. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
132. Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal Microscopy
133. Assessment of Pancreatic Islet Mass after Islet Transplantation Using In Vivo Bioluminescence Imaging
134. Malignant insulinoma
135. Pulmonary Angiography for the Diagnosis of Thromboembolic Events in the Non-Human Primate
136. Resistin serum levels in type 1 diabetes pre- and post-islet transplantation
137. Induction of Diabetes in Nonhuman Primates by Means of Temporary Arterial Embolization and Selective Arterial Injection of Streptozotocin
138. RABBIT ANTITHYMOCYTE GLOBULIN INDUCTION AND SIROLIMUS MONOTHERAPY SUPPORTS PROLONGED ISLET ALLOGRAFT FUNCTION IN A NONHUMAN PRIMATE ISLET TRANSPLANTATION MODEL
139. Islet transplantation: where do we stand now?
140. Oligonucleotide Microarray Analysis of Intact Human Pancreatic Islets: Identification of Glucose-Responsive Genes and a Highly Regulated TGFβ Signaling Pathway
141. Zuclopenthixol-Associated Neutropenia and Thrombocytopenia
142. A dangerous complication of chronic sinusitis
143. Lack of Mediastinal Shift as a Clue to Delayed Postpneumonectomy Empyema
144. 6;9 Translocation in Myelodysplastic Syndrome
145. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma
146. Esophageal Perforation After Transesophageal Echocardiogram
147. Authors' reply
148. Asymptomatic temporary atrioventricular dissociation complicating meningococcal meningitis
149. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
150. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure1 <FN ID="FN1"><NO>1</NO>No competing interests declared.</FN>
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.